Weekly 24-hour infusion of high-dose 5-fluorouvacil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer

被引:16
作者
Kretzschmar, A
Reichardt, P
Thuss-Patience, PC
Hohenberger, P
Benter, T
Dörken, B
Köhne, CH
机构
[1] Humboldt Univ, Dept Internal Med, D-1086 Berlin, Germany
[2] Humboldt Univ, Dept Hematol, D-1086 Berlin, Germany
[3] Humboldt Univ, Dept Oncol, D-1086 Berlin, Germany
[4] Humboldt Univ, Dept Tumorimmunol, D-1086 Berlin, Germany
[5] Humboldt Univ, Charite, Robert Rossle Hosp, Dept Surg & Surg Oncol, D-1086 Berlin, Germany
关键词
folinic acid; gastric cancer; 5-fluorouracil; mitomycin C;
D O I
10.1159/000012130
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer. Patients and Methods: Chemonaive patients with locally advanced inoperable, recurrent or metastatic gastric cancer were treated with 15 mg/m(2) i.v, mitomycin C as bolus on day 1 of a 7-week cycle followed by a 2-hour infusion of folinic acid (500 mg/m(2)) and a 24-hour infusion of 5-FU (2,600 mg/m(2)) given on days 1, 8, 15, 22, 29, and 36 as outpatient treatment. Results: Thirty evaluable patients (median age 58 years and median ECOG performance status 1) received 1-4 cycles (median 3). 53% of the patients had liver metastases. Treatment-related toxicity was low with 10% of patients experiencing diarrhea greater than or equal to grade 3, 3% mucositis grade 3 and 3% nausea grade 3 (CTC). Hematological toxicity was mild with 13% thrombopenia grade 3 and no leukopenia grade 4. Eleven patients achieved a partial remission (major response rate 37%; 95% confidence interval 22-53%). Median time to progression was 5 months and median overall survival time was 7 months. Conclusion: This regimen is a well-tolerated outpatient treatment for patients with advanced gastric cancer with efficacy being comparable to other chemotherapy protocols. Copyright (C) 2000 S. Karger AG, Basel.
引用
收藏
页码:14 / 17
页数:4
相关论文
共 19 条
[1]  
Ajani JA, 1998, ONCOLOGY-NY, V12, P44
[2]  
BECKER K, 1997, P AN M AM SOC CLIN, V16, pA283
[3]  
CERVANTES A, 1997, P AM SOC CLIN ONCOL, V16, pA284
[4]   Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer [J].
Glimelius, B ;
Ekstrom, K ;
Hoffman, K ;
Graf, W ;
Sjoden, PO ;
Haglund, U ;
Svensson, C ;
Enander, LK ;
Linne, T ;
Sellstrom, H ;
Heuman, R .
ANNALS OF ONCOLOGY, 1997, 8 (02) :163-168
[5]  
Hsu CH, 1997, ONCOLOGY, V54, P275
[6]  
MURAD AM, 1993, CANCER, V72, P37, DOI 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO
[7]  
2-P
[8]   RANDOMIZED CLINICAL-TRIAL OF MITOMYCIN-C WITH OR WITHOUT PRETREATMENT WITH WR-2721 IN PATIENTS WITH ADVANCED COLORECTAL-CANCER [J].
POPLIN, EA ;
LORUSSO, P ;
LOKICH, JJ ;
GULLO, JJ ;
LEMING, PD ;
SCHULZ, JJ ;
VEACH, SR ;
MCCULLOCH, W ;
BAKER, L ;
SCHEIN, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 33 (05) :415-419
[9]   RANDOMIZED COMPARISON OF FLUOROURACIL, EPIDOXORUBICIN AND METHOTREXATE (FEMTX) PLUS SUPPORTIVE CARE WITH SUPPORTIVE CARE ALONE IN PATIENTS WITH NONRESECTABLE GASTRIC-CANCER [J].
PYRHONEN, S ;
KUITUNEN, T ;
NYANDOTO, P ;
KOURI, M .
BRITISH JOURNAL OF CANCER, 1995, 71 (03) :587-591
[10]   A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer [J].
Ross, P ;
Norman, A ;
Cunningham, D ;
Webb, A ;
Iveson, T ;
Padhani, A ;
Prendiville, J ;
Watson, M ;
Massey, A ;
Popescu, R ;
Oates, J .
ANNALS OF ONCOLOGY, 1997, 8 (10) :995-1001